Dupixent Secures EU Approval for Young Children with Chronic Urticaria, Expanding Key Market
REGN sits 57% above its 52-week low of $476.487.
Summary
Regeneron and Sanofi's blockbuster drug Dupixent has received European Union approval to treat young children aged two to 11 years with moderate-to-severe chronic spontaneous urticaria (CSU). This marks Dupixent as the first targeted medicine for this specific patient population in the EU, significantly expanding its addressable market for a key revenue-generating product. The approval is based on positive data from the LIBERTY-CUPID clinical study program, demonstrating Dupixent's efficacy and safety profile. This regulatory win is a material positive development, reinforcing Dupixent's market leadership and contributing to Regeneron's long-term revenue growth, following a recent mix of positive and negative news for the company. Investors will now watch for the outcome of the pending US supplemental biologics license application for the same indication.
At the time of this announcement, REGN was trading at $749.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.2B. The 52-week trading range was $476.49 to $821.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.